uniQure (NASDAQ:QURE) CEO Sells $291,628.89 in Stock

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 28,341 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the sale, the chief executive officer now owns 651,454 shares of the company’s stock, valued at approximately $6,703,461.66. This represents a 4.17 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $12.51 on Friday. The firm has a 50 day moving average of $14.59 and a 200-day moving average of $9.92. The stock has a market capitalization of $609.77 million, a PE ratio of -2.52 and a beta of 0.38. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on QURE. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from $20.00 to $52.00 in a research note on Tuesday, December 10th. Royal Bank of Canada restated an “outperform” rating and set a $24.00 target price on shares of uniQure in a research note on Tuesday, January 21st. Leerink Partners lifted their price objective on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Guggenheim reiterated a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of uniQure in a research note on Tuesday. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and a consensus target price of $38.89.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently made changes to their positions in QURE. RTW Investments LP acquired a new position in shares of uniQure in the 3rd quarter valued at approximately $49,000. Atria Investments Inc acquired a new position in shares of uniQure in the 3rd quarter valued at approximately $53,000. Quarry LP bought a new stake in shares of uniQure during the 3rd quarter valued at approximately $58,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of uniQure during the 3rd quarter valued at approximately $69,000. Finally, Twin Tree Management LP bought a new stake in shares of uniQure during the 4th quarter valued at approximately $77,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.